Related Experiment Video
Updated: Jun 17, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Current controversies in heart failure with a preserved ejection fraction
1Consultant cardiologist, Department of Cardiology, Taunton & Somerset Hospital, Musgrove Park, Taunton, TA1 5DA, UK. david.maciver@tst.nhs.uk
Future Cardiology
|December 18, 2009
Summary
Heart failure with preserved ejection fraction (HFpEF) remains poorly understood, with ongoing debates in its nomenclature and pathogenesis. This review clarifies controversies and theories surrounding HFpEF to improve diagnosis and clinical trial interpretation.
Area of Science:
- Cardiology
- Internal Medicine
- Pathophysiology
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome with significant diagnostic and therapeutic challenges.
- Existing controversies regarding HFpEF nomenclature and pathogenesis hinder consistent diagnosis and clinical trial design.
- The heterogeneity of HFpEF contributes to difficulties in understanding its underlying mechanisms.
Purpose of the Study:
- To examine contemporary theories and mechanistic studies related to HFpEF.
- To clarify existing controversies and divergent opinions on HFpEF nomenclature and pathogenesis.
- To provide a framework for resolving scientific disputes and improving the understanding of HFpEF.
Main Methods:
- Literature review of contemporary theories and mechanistic studies on HFpEF.
- Analysis of controversies surrounding HFpEF nomenclature and pathogenesis.
- Synthesis of evidence to resolve divergent opinions on HFpEF.
Main Results:
- Nomenclature debates reflect a fundamental lack of understanding of HFpEF pathogenesis.
- Inconsistent diagnostic criteria contribute to challenges in patient selection for clinical trials.
- Resolving theoretical divergences is crucial for advancing HFpEF research and treatment.
Conclusions:
- Clarifying HFpEF nomenclature and pathogenesis is essential for advancing the field.
- Improved understanding will lead to more consistent diagnoses and better-designed clinical trials.
- This review aims to reconcile divergent opinions and foster consensus on HFpEF.
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...